Antimicrobial peptide, lumbricusin, ameliorates motor dysfunction and dopaminergic neurodegeneration in a mouse model of parkinson’s disease

Journal of Microbiology and Biotechnology

Volumn 25, Issue 10, 2015, Pages 1640-1647

  Kim, Dae Hong ^a   Lee, Ik Hwan ^a   Nam, Seung Taek ^a   Hong, Ji ^a   Zhang, Peng ^a   Lu, Li Fang ^a   Hwang, Jae Sam ^b   Park, Ki Cheol ^c   Kim, Ho ^a  

^a Daejin University   (South Korea)

^b National Institute of Animal Science   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Antimicrobial peptide; Cell cycle arrest; Cell proliferation (neurotropine); Neuroprotective activity; P27Kip1; Parkinson s disease; Proteasomal protein degradation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOPAMINE; LUMBRICUSIN; OXIDOPAMINE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; HELMINTH PROTEIN; LUMBRICUSIN PEPTIDE, LUMBRICUS TERRESTRIS; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NEURAL STEM CELL; NEUROPROTECTION; NEWBORN; NONHUMAN; PARKINSON DISEASE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; CELL CULTURE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; METABOLISM; MOTOR DISORDERS; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HELMINTH PROTEINS; MICE; MOTOR DISORDERS; NEURAL STEM CELLS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84945256557     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1507.07011     Document Type: Article

References (32)

1. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. 2012. Minocycline benefits negative symptoms in early schizophrenia: a randomised double- blind placebo-controlled clinical trial in patients on standard 1646 Kim et al. treatment. J. Psychopharmacol. 26: 1185-1193.
2. Chen LW, Yung KK, Chan YS. 2004. Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson’s disease. Curr. Drug Targets 5: 197-206.
3. da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, et al. 2011. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. CNS Neurol. Disord. Drug Targets 10: 251-270.
4. Dixit A, Srivastava G, Verma D, Mishra M, Singh PK, Prakash O, Singh MP. 2013. Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease. Biochim. Biophys. Acta 1832: 1227-1240.
5. Eggert A, Ikegaki N, Liu X, Chou TT, Lee VM, Trojanowski JQ, Brodeur GM. 2000. Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. Oncogene 19: 2043-2051.
6. Garcia C, Palomo-Garo C, Garcia-Arencibia M, Ramos J, Pertwee R, Fernandez-Ruiz J. 2011. Symptom-relieving and neuroprotective effects of the phytocannabinoid delta(9)-THCV in animal models of Parkinson’s disease. Br. J. Pharmacol. 163: 1495-1506.
7. Gupta A, Kumar A, Kulkarni SK. 2011. Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 35: 974-981.
8. Hoehn MM, Yahr MD. 1967. Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
9. Hwang DY, Fleming SM, Ardayfio P, Moran-Gates T, Kim H, Tarazi FI, et al. 2005. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. 25: 2132-2137.
10. Kang BR, Kim H, Nam SH, Yun EY, Kim SR, Ahn MY, et al. 2012. CopA3 peptide from Copris tripartitus induces apoptosis in human leukemia cells via a caspase-independent pathway. BMB Rep. 45: 85-90.
11. Kang JK, Chang CH, Nam HJ, Kim SK, Ahn KJ, Seok H, et al. 2011. Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells. Cell. Oncol. (Dordr). 34: 11-21.
12. Kang JK, Hwang JS, Nam HJ, Ahn KJ, Seok H, Kim SK, et al. 2011. The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity. Antimicrob. Agents Chemother. 55: 4850-4857.
13. Kim DH, Lee IH, Nam ST, Hong J, Zhang P, Hwang JS, et al. 2014. Neurotropic and neuroprotective activities of the earthworm peptide Lumbricusin. Biochem. Biophys. Res. J. Microbiol. Biotechnol. Commun. 448: 292-297.
14. Kim H, Kokkotou E, Na X, Rhee SH, Moyer MP, Pothoulakis C, Lamont JT. 2005. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 129: 1875-1888.
15. Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, et al. 2005. Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J. Biol. Chem. 280: 21237-21245.
16. Kwon SH, Hong SI, Jung YH, Kim MJ, Kim SY, Kim HC, et al. 2012. Lonicera japonica THUNB. protects 6-hydroxydopamine-induced neurotoxicity by inhibiting activation of MAPKs, PI3K/Akt, and NF-kappaB in SH-SY5Y cells. Food Chem. Toxicol. 50: 797-807.
17. Laganiere J, Kells AP, Lai JT, Guschin D, Paschon DE, Meng X, et al. 2010. An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson’s disease. J. Neurosci. 30: 16469-16474.
18. Li Y, Luo F, Wei L, Liu Z, Xu P. 2011. Knockdown of glycogen synthase kinase 3 beta attenuates 6-hydroxydopamine-induced apoptosis in SH-SY5Y cells. Neurosci. Lett. 487: 41-46.
19. Lin CJ, Chen HJ, Lo YC. 2011. Ergonomic investigation of weight distribution of laparoscopic instruments. J. Laparoendosc. Adv. Surg. Tech. A 21: 411-415.
20. Litteljohn D, Mangano E, Clarke M, Bobyn J, Moloney K, Hayley S. 2010. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease. Parkinsons Dis. 2011: 713517.
21. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. 1998. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry 64: 314-319.
22. Munoz U, Bartolome F, Bermejo F, Martin-Requero A. 2008. Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer’s dementia patients. Neurobiol. Aging 29: 1474-1484.
23. Nam HJ, Oh AR, Nam ST, Kang JK, Chang JS, Kim DH, et al. 2012. The insect peptide CopA3 inhibits lipopolysaccharide- induced macrophage activation. J. Pept. Sci. 18: 650-656.
24. Nam ST, Kim DH, Lee MB, Nam HJ, Kang JK, Park MJ, et al. 2013. Insect peptide CopA3-induced protein degradation of p27Kip1 stimulates proliferation and protects neuronal cells from apoptosis. Biochem. Biophys. Res. Commun. 437: 35-40.
25. Ohta M, Mizuta I, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S. 2000. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 272: 18-22.
26. Qiu J, Takagi Y, Harada J, Topalkara K, Wang Y, Sims JR, et al. 2009. p27Kip1 constrains proliferation of neural progenitor cells in adult brain under homeostatic and ischemic conditions. Stem Cells 27: 920-927.
27. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. 2010. Neurotrophic factor therapy for Parkinson’s disease. Prog. Brain Res. 184: 237-264.
28. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77.
29. Sharma NK, Sethy NK, Meena RN, Ilavazhagan G, Das M, Bhargava K. 2011. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia Neuroprotective Effect of an Antimicrobial Peptide 1647 induced oxidative stress in rat brain. Peptides 32: 1217-1224.
30. Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z, Van den Haute C, Baekelandt V. 2006. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson’s disease. Mol. Ther. 14: 716-723.
31. Wallen A, Perlmann T. 2003. Transcriptional control of dopamine neuron development. Ann. NY Acad. Sci. 991: 48-60.
32. Yoo J, Seo JJ, Eom JH, Hwang DY. 2012. Effects of stromal cell-derived factor 1alpha delivered at different phases of transient focal ischemia in rats. Neuroscience 209: 171-186.